Bimekizumab as-needed dosing in patients with psoriasis: a case series
Larger prospective studies comparing efficacy and safety of this off-label, as needed, bimekizumab dosing regimen with standard on-label dosing are necessary to corroborate these findings.
Authors
- Emilio Berná‐Rico (ORCID: https://orcid.org/0000-0003-0348-5421)
- Carlota Abbad‐Jaime de Aragón (ORCID: https://orcid.org/0000-0002-5587-1204)
- Álvaro González‐Cantero (ORCID: https://orcid.org/0000-0001-8060-4784)
- Pedro Jaen-Olasolo (ORCID: https://orcid.org/0000-0002-7334-0044)
- Andrew Blauvelt (ORCID: https://orcid.org/0000-0002-2633-985X)
Institutions
- Universidad Francisco de Vitoria (ES)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- Hospital Universitario Ramón y Cajal (ES)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1080/09546634.2025.2492197
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00